UDT Billing: Medical Necessity Per Test, Per Patient, Per Date

Why drug-test billing is an enforcement magnet

Urine drug testing draws enforcement attention out of proportion to its clinical footprint because it has the profile fraud detection is built to catch: a high-dollar service that can be ordered repeatedly, in bulk, on a standing protocol. When a claim is not backed by individualized medical necessity, the False Claims Act treats it as a false claim — treble damages, per-claim penalties, and a reckless-disregard standard 1Ref 1U.S. Department of Justice (2026).The False Claims Act.That the FCA imposes treble damages and per-claim penalties for knowingly submitting false claims, and that 'knowingly' includes reckless disregard — the exposure a repetitive testing protocol multiplies..

The FCA and the solo practice are not a mismatch: a single knowingly unsupported claim is enough, and a repetitive testing protocol multiplies that one claim into hundreds. Multiply an unsupported test across a panel, across every patient, across every visit, and the exposure compounds fast — which is why analytics flag drug-test billing early and why the dollar figures in these cases run large.

Medical necessity per test, per patient, per date

The discipline that keeps drug-test billing clean is medical necessity documented per test, per patient, and per date of service — not a frequency baked into a template or a panel ordered the same way for everyone. Each test on a panel needs a reason tied to that patient's clinical picture on that day; each date of testing needs its own justification.

A protocol that orders the same large panel at every visit, regardless of the individual, is the single most common finding in these cases. Two habits protect you:

• Order to the patient, not the template. The size of the panel and the interval between tests both flow from the individual's clinical situation.
• Write the reason down at the time. A necessity note contemporaneous with the order is what lets you answer an audit with the record rather than a reconstruction.

Presumptive vs definitive — and the CLIA line

Two testing tiers sit behind the billing, and conflating them is a recurring problem. Presumptive testing gives a quick positive-or-negative screen; definitive testing identifies and quantifies specific substances and reimburses at substantially higher rates. Payers generally expect definitive testing to be ordered only when the presumptive result or the clinical situation makes it necessary — not reflexively on every specimen.

Routinely billing definitive testing where a presumptive screen would answer the clinical question is exactly the pattern enforcement targets. Which tests you can run in your own office depends on your CLIA certificate and its scope — the CLIA certificate of waiver and the waived-test menu are their own topic, and running a test your certificate does not cover creates a billing problem on top of any necessity question. Match the tier to the clinical need, and document why the more expensive tier was warranted whenever you reach for it.

Reference-lab kickbacks: the arrangement that turns billing into a case

The arrangement that most reliably turns drug-test billing into a fraud case is the reference-lab kickback. A lab that wants your specimens may offer something of value to get them — payments dressed as processing or specimen-handling fees, free point-of-care cups, discounted supplies, or waived charges. Anything of value exchanged to induce the referral of federally reimbursable testing is the classic anti-kickback problem. The safe harbors define which arrangements are protected — bona fide employment, personal services with compensation set in advance at fair market value, equipment rental — each with required elements 2Ref 2Office of the Federal Register (2026).42 CFR 1001.952 — Exceptions (Anti-Kickback Safe Harbors).That the anti-kickback safe harbors protect defined arrangements — employment, personal services at fair market value, equipment rental — each with required elements a specimen-referral inducement cannot meet..

When you cannot tell whether a lab arrangement crosses the line, the OIG's published advisory opinions on specific arrangements show how it reasons 3Ref 3HHS Office of Inspector General (2026).Advisory Opinions.That the OIG issues and publishes advisory opinions on whether specific arrangements — including lab relationships — implicate the anti-kickback statute.. This is also where a professional courtesy is misread — waiving a charge as a courtesy is not the same as a compliant financial arrangement with a lab, and the elements decide it. The safe question for any lab offer: am I receiving fair value for defined work, or something tied to the volume of specimens I send?

When the lab is yours: Stark and self-referral

If the lab is yours, a different statute joins the analysis. Clinical laboratory services are a designated health service under the Stark law, so a physician who refers Medicare or Medicaid drug testing to a lab the physician owns is self-referring — permitted only if the in-office ancillary services exception, or another exception, is met 4Ref 4Centers for Medicare & Medicaid Services (2026).Physician Self-Referral.That Stark is strict-liability and bars a physician from referring designated health services — which include clinical laboratory services — to an entity the physician owns unless an exception applies..

Stark is strict-liability: no bad intent is required, so a technical miss on an exception is still a violation. A solo physician who brings definitive testing in-house should confirm the exception's supervision, location, and billing conditions before the first referral, not after. Non-physician clinicians — psychologists, counselors, social workers — are outside Stark's definition of physician, but the anti-kickback and medical-necessity questions still apply to any testing they order or send out.

The controlled-substance context

Much drug testing sits inside controlled-substance care, and that context shapes both the necessity story and the recordkeeping. Providers who prescribe controlled substances already operate under the DEA's diversion-control registration and recordkeeping rules 5Ref 5Drug Enforcement Administration (2026).Diversion Control Division.That the DEA's Diversion Control Division administers practitioner registration and controlled-substance recordkeeping and inventory rules that prescribers already operate under.. Monitoring adherence and detecting diversion are common clinical reasons to test a patient on controlled-substance therapy.

But "the patient is on a controlled substance" is not, by itself, a standing justification for the same panel at every visit. The necessity still has to be individual: what clinical question does this test, for this patient, on this date, answer? A monitoring plan can absolutely support regular testing — it just has to be a plan grounded in the patient's risk and clinical course, documented as such, rather than a flat schedule applied to everyone on a prescription.

Staying clear — and what to do if you've drifted

Staying clear of a drug-testing case is mostly documentation and restraint. Order what the individual patient needs, document the reason per test and per date, keep the billing paper that ties each claim to a necessity note, and structure any lab relationship so it pays for defined work rather than volume. If you find you have already billed testing that the records do not support, the OIG maintains a Self-Disclosure Protocol for conduct implicating federal fraud laws, and coming forward mitigates exposure 6Ref 6HHS Office of Inspector General (2026).Health Care Fraud Self-Disclosure Protocol.That the OIG maintains a Self-Disclosure Protocol for conduct implicating federal fraud laws, and that coming forward through it mitigates exposure..

The consequences at the far end justify the caution: beyond repayment and penalties, the OIG can exclude an individual from federal programs, after which no federal payment may be made for their services 7Ref 7HHS Office of Inspector General (2026).Exclusions Program.That the OIG can exclude an individual from federal health programs, after which no federal program payment may be made for their services.. Bring in counsel when a lab offers anything of value for your specimens, when you are ordering definitive testing on a standing protocol, or when you cannot rule out a fraud statute. The same real-encounter logic runs through telehealth enforcement and drug-test billing alike — the claim has to match what actually, necessarily happened.